EICHORPublic-registry trials using Elecoglipron that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Elecoglipron appears in 1 registered trial Eichor's radar has found, sponsored by AstraZeneca, the most recent registered as Phase 3, with a planned enrollment of 7,000. Registered timeline: 2026–2030. The registry holds 5,725 registered studies for Chronic Kidney Disease.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | AstraZeneca | Chronic Kidney Disease | PHASE3 | 426 |
| Status | Not Yet Recruiting · planned start 2026-08 |
| Primary completion | 2030-10 |
| Enrollment target | 7,000 participants |
| Design | Randomized · Parallel · Phase 3 · 2 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 426 listed in Argentina, Australia, Brazil, Bulgaria |
All fields verbatim from the ClinicalTrials.gov record for NCT07753993.
| First registered study | April 2026 — NCT07534592 (AstraZeneca) |
| Registered studies matching this name | 9 all-time · 7 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 5,725 registered studies for Chronic Kidney Disease. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Chronic Kidney Disease studies · Weekly briefs
